QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass., February 05, 2025--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage ...

The drug in question, dubbed QLS‑111, has been created with Qlaris’ ATP-sensitive potassium channel modulator platform and is designed to lower intraocular pressure (IOP). The results ...

QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company ...

Kia’s official first-party NACS adapters are now ready to ship out, but owners will have to wait to use them on Tesla Superchargers until later this quarter. But for most vehicles, charging on ...